ClinicalTrials.gg
Sign In
CompletedNCT00743873Updated Jul 12, 2011

Platelet-rich Plasma (PRP) Treatment for Medial Retinaculum Tear Post Medial Patellar Dislocation

A Phase 2/3 interventional study of Plasma Rich in Growth Factors (PRGF) and placebo in Patella-Dislocation, sponsored by Meir Medical Center. Completed at 1 site in Israel. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2011-07-12.

Sponsored by Meir Medical Center · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

To check the influence of injected platelet-rich plasma (PRP) on the healing of medial retinaculum and the redaction in recurrent dislocation of the patella.

Read the detailed description

Autologous platelet-rich matrices may aid in the healing of ligaments \& tendons by promoting and accelerating tissue healing because of the release of growth factors including transforming growth factor (TGF)-beta1 and platelet-derived growth factor (PDGF) from platelet alpha-granules.

02

Conditions studied

  • Patella-Dislocation

Browse trials for

Keywords

  • medial retinaculum tear s/p patella dislocation
03

In context

Patellar Dislocation

41 studies on the registry are indexed under Patellar Dislocation; 9 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 22 interventional studies indexed under Patellar Dislocation.

Browse Patellar Dislocation studies →

Lead sponsor

Meir Medical Center is the lead sponsor of 401 studies on the registry; 26 are open to participants now.

Browse Meir Medical Center studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18-40 years old
  • first time patella dislocation

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • mental or physical disabilities
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Placebo comparator
    2

    saline

    Drug: placebo

  • Experimental
    1

    Plasma Rich in Growth Factors (PRGF)

    Biological: Plasma Rich in Growth Factors (PRGF)

Interventions

  • BiologicalPlasma Rich in Growth Factors (PRGF)

    US guided IM injection 3-6mg

    Also known as: platelet-derived preparation rich in growth factors

  • Drugplacebo

    injection of 6 cc of saline into injured area

    Also known as: saline 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. redaction in healing time and recurrence

    Time frame: 1 year

07

Study locations

1 site
  • Meir medical center
    Kfar Saba, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2008
First posted
Aug 29, 2008
Start
Jan 2008
Primary completionActual
Feb 2009
CompletionActual
Mar 2009
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00743873
Lead sponsor
Meir Medical Center
First posted
Aug 29, 2008
Start date
Jan 2008
Primary completion
Feb 2009
Completion
Mar 2009
Last update
Jul 12, 2011

Study contacts

Omer Mei Dan, Dr
principal investigator · Meir Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Other studies in this condition

Patellar Dislocation →

Other studies from this sponsor

Meir Medical Center →

Start the discussion